The Prostate Cancer Foundation Challenge Awards are specifically designed to provide financial support to bold, cross-disciplinary research efforts that otherwise might struggle to secure funding. Dr. Khurana’s team, which notably includes Dr. Iman Hajirasouliha—associate professor at Weill Cornell Medicine—and physician-scientist Dr. Yu Chen alongside pathologist Dr. Anuradha Gopalan from Memorial Sloan Kettering Cancer Center, exemplifies the power of integrating diverse scientific disciplines to tackle complex biomedical challenges. Their joint mission focuses on leveraging advanced computational methodologies to combat the growing challenge of treatment-resistant prostate cancer.

Prostate cancer remains one of the most commonly diagnosed malignancies among men in the United States, with approximately 300,000 new cases identified annually. The lifetime risk of developing this disease stands at nearly 12%. Tradition dictates that prostate tumor proliferation is largely driven by androgen receptor signaling pathways, which can be disrupted therapeutically through androgen deprivation therapy or direct androgen receptor inhibitors. Despite the initial efficacy of such treatments, a significant subset of tumors evolve into aggressive subtypes that bypass these signaling dependencies, resulting in treatment resistance. Unfortunately, current clinical diagnostic tools lack the precision necessary to detect these resistant tumor phenotypes during their early emergence.

Building on foundational work that identified key treatment-resistant prostate tumor subtypes, Dr. Khurana and her collaborators aim to address this critical diagnostic gap through AI-driven innovation. Their strategy centers on training machine learning models using extensive datasets comprising digitized pathology slides, tumor gene expression profiles, and associated clinical treatment outcomes. By assimilating these multidimensional data, the AI system aspires to classify individual tumors accurately, revealing their subtype composition and predicting therapeutic responsiveness before conventional methods would allow.

The technical challenge lies in designing algorithms that not only achieve high sensitivity—minimizing false negatives—but also maintain specificity to avoid false positives, thereby ensuring clinical reliability. The trained models must interpret complex histopathological features, integrate transcriptomic signatures, and correlate these with treatment trajectories to generate predictive insights. Such a sophisticated AI platform could revolutionize patient stratification, enabling clinicians to identify candidates for experimental therapies tailored to resistant subtypes and simultaneously avoid ineffective standard treatments.

If successful, the AI classifiers developed through this project will fill a significant unmet need in urologic oncology by enabling early, non-invasive detection of tumor heterogeneity and adaptive resistance mechanisms. This capability has profound implications for personalized medicine, allowing therapeutic interventions to be precisely targeted at subpopulations of cancer cells poised to evade current treatments. This would herald a shift from a one-size-fits-all approach toward highly customized clinical management in prostate cancer care.

Looking beyond algorithm development, Dr. Khurana’s team plans to advance the AI model toward clinical validation via prospective trials. This stage will test the practical application of their technology in real-world diagnostic workflows, evaluating performance in diverse patient cohorts to ensure robustness and reproducibility at scale. Successful translation from computational model to bedside tool could accelerate drug development by refining patient selection for clinical trials of novel therapeutics.

This research initiative exemplifies the convergence of cutting-edge computational science and clinical oncology, illustrating how data-driven AI tools can empower clinicians with unprecedented diagnostic precision. The integration of pathology imaging, genomics, and AI encapsulates a modern multidisciplinary approach crucial for overcoming the biological complexity inherent in prostate cancer progression and drug resistance.

In summary, Dr. Ekta Khurana’s groundbreaking project, supported by the Prostate Cancer Foundation’s substantial award, promises to transform the landscape of prostate cancer diagnosis and treatment. By harnessing artificial intelligence to detect treatment-resistant tumor subtypes early, this work could significantly improve clinical outcomes for thousands of men facing advanced prostate malignancies. The collaborative effort from leading institutions underscores a new era where computational innovation and biomedical expertise unite to tackle some of the most formidable challenges in cancer care.

Subject of Research: Prostate cancer; AI-based early detection of treatment-resistant tumor subtypes
Article Title: AI-Powered Early Detection of Treatment-Resistant Prostate Tumors: A Paradigm Shift in Cancer Care
News Publication Date: Not specified
Web References:

• Prostate Cancer Foundation
• Weill Cornell Medicine – Dr. Ekta Khurana
• Weill Cornell Medicine – Dr. Iman Hajirasouliha
• Memorial Sloan Kettering Research – Dr. Yu Chen
• Memorial Sloan Kettering – Dr. Anuradha Gopalan
  Image Credits: Weill Cornell Medicine
  Keywords: Prostate cancer, Prostate tumors, Artificial intelligence, Treatment resistance, Computational biomedicine, Machine learning, Pathology, Genomics, Clinical trials

Prostate cancer remains the second-leading cause of cancer-related deaths among men in the United States, yet the majority of newly diagnosed cases involve slow-growing tumors that rarely progress to life-threatening stages. Conventional management for these low- to intermediate-risk tumors involves active surveillance, a strategic approach that prioritizes routine monitoring through blood-based prostate-specific antigen (PSA) tests, magnetic resonance imaging (MRI), and frequent biopsies to detect cancer progression. However, the invasiveness and potential complications of repeated biopsies, including infections and urinary difficulties, often lead to patient non-compliance and missed opportunities for timely intervention.

The PSMA-PET CT imaging modality deployed in this study employs a radiotracer designed to bind specifically to the Prostate Specific Membrane Antigen—a transmembrane protein highly expressed on prostate cancer cells, especially in aggressive or metastatic forms. This radiotracer emits positrons detected by PET scanners, allowing clinicians to obtain highly sensitive and precise three-dimensional images reflecting cancer localization and extent at a molecular level. PSMA-PET CT has already established clinical utility in diagnosing metastatic and recurrent prostate cancers, but its potential role in primary tumor surveillance remains to be elucidated.

Under the leadership of Dr. Timothy McClure, an assistant professor specializing in both urology and interventional radiology at Weill Cornell Medicine, the trial will enroll 200 men with clinically classified low or intermediate-risk prostate cancer who have elected active surveillance over immediate treatment. Participants will undergo standard surveillance regimens supplemented by PSMA-PET CT imaging. The objective is to assess whether this imaging enhancement can improve the accuracy of detecting cancers that necessitate therapeutic intervention, thereby reducing unnecessary biopsies and their associated morbidities.

The trial is distinguished not only by its ambitious clinical endpoints but also by its collaborative scope, spanning NewYork-Presbyterian/Weill Cornell Medical Center and four additional prominent institutions. This multi-center approach is poised to yield robust data reflective of diverse patient populations and clinical practices. Additionally, the study benefits from financial and scientific support from Lantheus, the manufacturing company behind the diagnostic agents integral to PSMA-PET CT technology.

Concurrently, Dr. McClure is collaborating with Dr. Mert Sabuncu, Vice Chair of Radiology Research and a professor of electrical engineering with expertise in machine learning, to develop sophisticated algorithms capable of predicting which prostate cancer patients are most likely to experience disease progression requiring intervention. Leveraging multimodal data—including imaging, clinical parameters, and genomic profiles derived from PSA blood samples—this artificial intelligence-driven approach aspires to refine individualized risk stratification and personalize surveillance strategies effectively.

The integration of machine learning with advanced imaging marks a significant step forward in precision oncology. Computational models trained on comprehensive datasets can discern nuanced patterns undetectable through conventional analysis, potentially identifying subtle indicators of tumor aggressiveness early in their development. If successful, this could streamline patient management by distinguishing individuals who genuinely need treatment from those who can safely continue observation.

Genomic analyses embedded within the study will also offer invaluable insights into the biological underpinnings of prostate cancer heterogeneity. By correlating imaging findings with genetic signatures associated with progression risk, researchers aim to establish non-invasive biomarkers that can dictate therapeutic decision-making. This paves the way for a paradigm shift away from "one-size-fits-all" approaches toward tailored care based on molecular profiles.

The broader implications of this study extend into health economics and patient quality of life. The current biopsy-dependent surveillance model imposes significant costs and patient burden—frequent hospital visits, procedure-related discomfort, and risk of complications. Validating PSMA-PET CT as an effective alternative imaging biomarker could diminish the frequency of invasive procedures, resulting in cost savings for healthcare systems and reducing anxiety and morbidity for patients.

Moreover, this research exemplifies how cross-sector collaboration—uniting academic researchers, clinical experts, industry partners, and bioengineers—can propel innovation in cancer diagnostics. By integrating cutting-edge radiopharmaceuticals, imaging technologies, and computational tools, this project endeavors to create a new standard for prostate cancer care that balances efficacy, safety, and patient-centeredness.

Dr. McClure emphasizes, "Our goal is to recalibrate the surveillance process by adopting less invasive yet more precise diagnostic methods, thereby improving patient outcomes and optimizing resource utilization. This trial could herald a new era in prostate cancer management, where we are better equipped to distinguish which patients truly need therapeutic intervention."

The study’s significance is further underscored by the alarming fact that many men discontinue active surveillance due to biopsy-related adverse events and discomfort, potentially leading to missed early detection of cancer progression. By mitigating these barriers with PSMA-PET CT and predictive analytics, this research holds promise to enhance adherence to monitoring protocols, thereby reducing both overtreatment and undertreatment risks.

As prostate cancer incidence continues to rise globally, innovations emerging from this clinical trial may set a precedent for other cancers monitored via active surveillance. The adoption of targeted molecular imaging combined with AI-driven predictive models could redefine chronic disease surveillance across oncology, heralding a new era where malignancies are managed with unprecedented accuracy and minimal invasiveness.

In summary, this extensive investigation funded by the NCI represents a pioneering effort to harness the synergy of molecular imaging and machine learning for prostate cancer surveillance. If successful, it will offer a transformative framework to reduce unnecessary biopsies, personalize patient management, and ultimately improve survival and quality of life for men grappling with the uncertainty of prostate cancer.

Subject of Research: Clinical trial assessing the utility of PSMA-PET CT imaging combined with active surveillance protocols for low- to intermediate-risk prostate cancer.

Article Title: Weill Cornell Medicine Launches Pioneering Clinical Trial Using PSMA-PET Imaging to Transform Prostate Cancer Surveillance

News Publication Date: May 9, 2025

Web References:
Dr. Timothy McClure Profile
Dr. Mert Sabuncu Profile

References: The research is supported in part by National Cancer Institute grant number 5R37CA282407.

Image Credits: NewYork-Presbyterian

Keywords: Prostate cancer, PSMA-PET CT, active surveillance, biopsies, molecular imaging, clinical trials, machine learning, predictive algorithms, health innovation, diagnostic imaging